{"downloaded": true, "htmlmade": false, "full": {"id": "29807781", "source": "MED", "pmid": "29807781", "pmcid": "PMC6037129", "fullTextIdList": {"fullTextId": "PMC6037129"}, "doi": "10.1016/j.ymthe.2018.05.003", "title": "Dominant-Negative TGF-\u03b2 Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.", "authorString": "Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH.", "authorList": {"author": [{"fullName": "Kloss CC", "firstName": "Christopher C", "lastName": "Kloss", "initials": "CC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Smilow Center for Translational Research, 3400 Civic Center Blvd., Philadelphia, PA 19104-5156, USA. Electronic address: klosschr@pennmedicine.upenn.edu."}}}, {"fullName": "Lee J", "firstName": "Jihyun", "lastName": "Lee", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA."}}}, {"fullName": "Zhang A", "firstName": "Aaron", "lastName": "Zhang", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA."}}}, {"fullName": "Chen F", "firstName": "Fang", "lastName": "Chen", "initials": "F", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA."}}}, {"fullName": "Melenhorst JJ", "firstName": "Jan Joseph", "lastName": "Melenhorst", "initials": "JJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Parker Institute for Cancer at the University of Pennsylvania, Philadelphia, PA 19104-5156, USA."}}}, {"fullName": "Lacey SF", "firstName": "Simon F", "lastName": "Lacey", "initials": "SF", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA."}}}, {"fullName": "Maus MV", "firstName": "Marcela V", "lastName": "Maus", "initials": "MV", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA."}}}, {"fullName": "Fraietta JA", "firstName": "Joseph A", "lastName": "Fraietta", "initials": "JA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Parker Institute for Cancer at the University of Pennsylvania, Philadelphia, PA 19104-5156, USA."}}}, {"fullName": "Zhao Y", "firstName": "Yangbing", "lastName": "Zhao", "initials": "Y", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA."}}}, {"fullName": "June CH", "firstName": "Carl H", "lastName": "June", "initials": "CH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Parker Institute for Cancer at the University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Smilow Center for Translational Research, 3400 Civic Center Blvd., Philadelphia, PA 19104-5156, USA. Electronic address: cjune@upenn.edu."}}}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "7", "volume": "26", "journalIssueId": "2704190", "dateOfPublication": "2018 Jul", "monthOfPublication": "7", "yearOfPublication": "2018", "printPublicationDate": "2018-07-01", "journal": {"title": "Molecular therapy : the journal of the American Society of Gene Therapy", "ISOAbbreviation": "Mol Ther", "medlineAbbreviation": "Mol Ther", "NLMid": "100890581", "ISSN": "1525-0016", "ESSN": "1525-0024"}}, "pubYear": "2018", "pageInfo": "1855-1866", "abstractText": "Cancer has an impressive ability to evolve multiple processes to evade therapies. While immunotherapies and vaccines have shown great promise, particularly in certain solid tumors such as prostate cancer, they have been met with resistance from tumors that use a multitude of mechanisms of immunosuppression to limit effectiveness. Prostate cancer, in particular, secretes transforming growth factor \u03b2 (TGF-\u03b2) as a means to inhibit immunity while allowing for cancer progression. Blocking TGF-\u03b2 signaling in T\u00a0cells increases their ability to infiltrate, proliferate, and mediate antitumor responses in prostate cancer models. We tested whether the potency of chimeric antigen receptor (CAR) T\u00a0cells directed to prostate-specific membrane antigen (PSMA) could be enhanced by the co-expression of a dominant-negative TGF-\u03b2RII (dnTGF-\u03b2RII). Upon expression of the dominant-negative TGF-\u03b2RII in CAR T\u00a0cells, we observed increased proliferation of these lymphocytes, enhanced cytokine secretion, resistance to exhaustion, long-term in\u00a0vivo persistence, and the induction of tumor eradication in aggressive human prostate cancer mouse models. Based on our observations, we initiated a phase I clinical trial to assess these CAR T\u00a0cells as a novel approach for patients with relapsed and refractory metastatic prostate cancer (ClinicalTrials.gov: NCT03089203).", "affiliation": "Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA; Smilow Center for Translational Research, 3400 Civic Center Blvd., Philadelphia, PA 19104-5156, USA. Electronic address: klosschr@pennmedicine.upenn.edu.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Research Support, Non-U.S. Gov't", "research-article", "Clinical Trial, Phase I", "Journal Article"]}, "grantsList": {"grant": {"grantId": "T32 CA009140", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Prostate", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "T-Lymphocytes", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Cell Line"}, {"majorTopic_YN": "N", "descriptorName": "Cell Line, Tumor"}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Prostatic Neoplasms", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Glutamate Carboxypeptidase II", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Transforming Growth Factor beta", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Receptors, Transforming Growth Factor beta", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Antigens, Surface", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Lymphocyte Activation", "meshQualifierList": {"meshQualifier": {"abbreviation": "PH", "qualifierName": "physiology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Cell Proliferation", "meshQualifierList": {"meshQualifier": {"abbreviation": "PH", "qualifierName": "physiology", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Receptors, Chimeric Antigen", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "PC-3 Cells"}]}, "keywordList": {"keyword": ["TGF-\u03b2", "prostate cancer", "Chimeric Antigen Receptor"]}, "chemicalList": {"chemical": [{"name": "Antigens, Surface", "registryNumber": "0"}, {"name": "Transforming Growth Factor beta", "registryNumber": "0"}, {"name": "Receptors, Transforming Growth Factor beta", "registryNumber": "0"}, {"name": "Glutamate Carboxypeptidase II", "registryNumber": "EC 3.4.17.21"}, {"name": "FOLH1 protein, human", "registryNumber": "EC 3.4.17.21"}, {"name": "Receptors, Chimeric Antigen", "registryNumber": "0"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1016/j.ymthe.2018.05.003"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6037129"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6037129?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1016/j.ymthe.2018.05.003"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "87", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-06-26", "dateOfCreation": "2018-05-30", "firstIndexDate": "2018-05-30", "fullTextReceivedDate": "2020-07-09", "dateOfRevision": "2021-01-09", "electronicPublicationDate": "2018-05-08", "firstPublicationDate": "2018-05-08", "embargoDate": "2019-07-05"}, "abstract": "Cancer has an impressive ability to evolve multiple processes to evade therapies. While immunotherapies and vaccines have shown great promise, particularly in certain solid tumors such as prostate cancer, they have been met with resistance from tumors that use a multitude of mechanisms of immunosuppression to limit effectiveness. Prostate cancer, in particular, secretes transforming growth factor \u03b2 (TGF-\u03b2) as a means to inhibit immunity while allowing for cancer progression. Blocking TGF-\u03b2 signaling in T\u00a0cells increases their ability to infiltrate, proliferate, and mediate antitumor responses in prostate cancer models. We tested whether the potency of chimeric antigen receptor (CAR) T\u00a0cells directed to prostate-specific membrane antigen (PSMA) could be enhanced by the co-expression of a dominant-negative TGF-\u03b2RII (dnTGF-\u03b2RII). Upon expression of the dominant-negative TGF-\u03b2RII in CAR T\u00a0cells, we observed increased proliferation of these lymphocytes, enhanced cytokine secretion, resistance to exhaustion, long-term in\u00a0vivo persistence, and the induction of tumor eradication in aggressive human prostate cancer mouse models. Based on our observations, we initiated a phase I clinical trial to assess these CAR T\u00a0cells as a novel approach for patients with relapsed and refractory metastatic prostate cancer (ClinicalTrials.gov: NCT03089203).", "Keywords": ["TGF-\u03b2", "prostate cancer", "Chimeric Antigen Receptor"], "journaltitle": "Molecular therapy : the journal of the American Society of Gene Therapy", "authorinfo": ["Kloss CC", "Lee J", "Zhang A", "Chen F", "Melenhorst JJ", "Lacey SF", "Maus MV", "Fraietta JA", "Zhao Y", "June CH"], "title": "Dominant-Negative TGF-\u03b2 Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication."}